Back to Search
Start Over
Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls
- Source :
- Therapeutic Advances in Gastroenterology, Vol 9 (2016)
- Publication Year :
- 2016
- Publisher :
- SAGE Publishing, 2016.
-
Abstract
- Inflammatory bowel disease (IBD) is a chronic, often relapsing, condition that deeply impacts the quality of life for many patients. Although there have been significant advances in medical treatments, a large proportion of patients become refractory to available therapeutic options. Stem-cell therapy through hematopoietic stem cells (HSCs) or mesenchymal stem (stromal) cells (MSCs) is a promising therapeutic option for severe refractory cases especially when surgery is not feasible. In HSC transplantation, the objective is to destroy the ‘autoreactive’ immune cells responsible for disease chronicity, and to re-establish gut tolerance to gut microbes. In perianal Crohn’s disease (CD), the objective is to deposit MSCs locally in fistulizing tracts to down-regulate the local immune response and induce wound healing. Results from upcoming and ongoing clinical trials will set the path of these novel therapeutic options that have the capability to successfully treat severe refractory Crohn’s patients.
- Subjects :
- Diseases of the digestive system. Gastroenterology
RC799-869
Subjects
Details
- Language :
- English
- ISSN :
- 1756283X and 17562848
- Volume :
- 9
- Database :
- Directory of Open Access Journals
- Journal :
- Therapeutic Advances in Gastroenterology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.00a6c569e3fa4c29b0425046a422859d
- Document Type :
- article
- Full Text :
- https://doi.org/10.1177/1756283X16642190